The Latin America, Middle East and Africa Vulvovaginal Candidiasis Treatment Market would witness market growth of 7.9% CAGR during the forecast period (2022-2028).
Self-treatment of VVC by using available OTC vaginal antifungals is considered an efficient way to treat patients with infrequent and uncomplicated episodes of vulvovaginal candidiasis. It is crucial to differentiate between vulvovaginal candidiasis and other causes of vaginal infections, such as bacterial vaginosis, to get appropriate treatment on time. Pharmacists may suggest using vaginal screening kits to confirm or identify the occurrence of vulvovaginal candidiasis. These kits are equally accurate as the standard diagnostics testing for vulvovaginal candidiasis.
In addition, the patients are suggested to undergo a proper medical diagnosis in case of the first episode of VVC when the woman is pregnant. Nearly all OTC vaginal antifungal products are approved for the treatment of vulvovaginal candidiasis. Single-dose oral treatment or short-course topical formulations are considered effective in treating most uncomplicated cases.
Vulvovaginal candidiasis is a common yeast infection usually caused by Candida albicans. However, various non Albicans species are also linked with the occurrence of VVC. These non-albicans species include C. tropicalis, C. parapsilosis, and C. glabrata. One of the symptoms of vulvovaginal candidiasis is abnormal white floccular discharge. The vulvovaginal candidiasis could be diagnosed by undergoing a physical examination combining the presence of blastospores or hyphae on KOH preparation.
The middle east region offers great growth potential to marketers in the pharmaceutical industry. This is due to the government's support for the growth of healthcare services, favorable economic factors, and the rollout of compulsive health insurance schemes. Furthermore, the government in the region is widely investing in the digital transformation of the healthcare sector. Also, due to the outspread of the pandemic, the Middle East's technology industry is growing rapidly. The outspread of the pandemic is opening doors for the pharmaceutical and telehealth sector. In addition, various women's health awareness programs have been launched by the regional government, which would further support the market expansion of vulvovaginal candidiasis treatment.
The Brazil market dominated the LAMEA Vulvovaginal Candidiasis Treatment Market by Country in 2021; thereby, achieving a market value of $24.4 million by 2028. The Argentina market is showcasing a CAGR of 8.4% during (2022 - 2028). Additionally, The UAE market would register a CAGR of 7.6% during (2022 - 2028).
Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Route of Administration, the market is segmented into Oral, Intravenous and Topical. Based on Drug Class, the market is segmented into Fluconazole, Clotrimazole, Terconazole, Terbinafine, Nystatin, Ketoconazole and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Vulvovaginal Candidiasis Treatment Market is Predict to reach $1.3 Billion by 2028, at a CAGR of 4.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Bristol Myers Squibb Company, Pfizer, Inc., Astellas Pharma, Inc., Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC), Basilea Pharmaceutica Ltd., Scynexis, Inc. and Grupo Ferrer Internacional S.A.
By Distribution Channel
By Route of Administration
By Drug Class
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
